This activity is supported by an educational grant from Merck & Co.
Immunotherapy: Advances and Updates
Anthony J. Olszanski, MD, RPH
Fox Chase Cancer Center
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Stanford Cancer Institute
One of the greatest advances in oncology over the past decade has been the recognition of cell surface proteins that are shown to play a key role in tumor immunogenicity; mechanisms in which tumors are able to avoid immune surveillance and destruction. Although immunotherapy is a relatively new approach to anti-cancer treatment, it is being utilized across multiple tumor types. This program highlights the science behind immunotherapy, immune-related adverse side effects (irAEs), monitoring and managing irAEs, the role of biomarkers, and differentiating pseudo-progression from actual disease progression.
These CME/CE/CPE accredited activities are jointly provided by